OnCusp Therapeutics, Inc.

CUSP06 is currently in early development and OnCusp has not yet established a recommended dose and schedule for the treatment of patients outside of its clinical trial. Additionally, in order to assure an adequate supply of investigational medicine for its clinical studies, OnCusp will retain the ability to manufacture and supply investigational medicines in a fair and equitable manner and in a volume that provides a suitable supply for ongoing clinical trials and development programs. Hence, currently, OnCusp is unable to provide its investigational medicines on an Expanded Access or Right to Try basis.